The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven.
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T h e ne w e ngl a nd jou r na l o f m e dicine C hagas' disease is the third most common parasitic disease globally, after malaria and schistosomiasis. 1 Chagas' cardiomyopathy is the most common form of nonischemic cardiomyopathy and one of the leading causes of complications and death in Latin America. 2 An estimated 6 million to 7 million persons are infected, and 36,800 new cases occur each year. Chagas' cardiomyopathy develops in approximately 25% of patients infected with Trypanosoma cruzi. [3] [4] [5] Chagas' disease has two phases: acute and chronic. Acute infection is usually a self-limited febrile illness. 6 In the chronic phase, cardiac or digestive complications develop in approximately one third of patients two or three decades after the acute infection. 7 Chronic Chagas' cardiomyopathy is associated with malignant arrhythmias, conduction disturbances, heart failure, and pulmonary and systemic embolism 2, 7 and is associated with an annual mortality of approximately 4% among patients who are followed in outpatient clinics. 8 T. cruzi causes an acute disease, which can be cured with trypanocidal treatment. 6 However, in chronic cardiomyopathy, the role of the parasite is debated and the effect of trypanocidal treatment is unclear. 9, 10 In some previous studies, autoimmune mechanisms were implicated as potential causes of late cardiac injury [11] [12] [13] [14] because of the apparent absence of parasites in the cardiac inflammatory lesions on classic histologic analysis and the occurrence of autoimmune responses related to polyclonal activation, molecular selfmimicry by parasite antigens, or cryptic epitopes shared by the host and parasites. 2, 14 However, the identification of T. cruzi antigens in inflamed myocardium with the use of sensitive techniques, such as immunohistochemical analysis and polymerase-chain-reaction (PCR) assay, suggests that parasite persistence may be an important factor that, in conjunction with individual host factors, triggers the inflammatory process. [14] [15] [16] In assessing whether trypanocidal therapy prevents or reduces cardiac disease, experimental models of chronic Chagas' infection have shown that trypanocidal therapy attenuates the pathologic consequences by reducing the parasite burden. 17, 18 A few small observational and randomized studies involving patients with chronic Chagas' disease have shown that benznidazole reduces the circulating parasite load, enhances seroconversion, and may halt the progression of cardiomyopathy. [19] [20] [21] [22] We designed the Benznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial to evaluate the efficacy and safety of benznidazole, as compared with placebo, in reducing clinical outcomes among patients with chronic Chagas' cardiomyopathy.
Me thods

Study Design
From 2004 through 2011, we conducted a randomized, double-blind, placebo-controlled trial in which we administered either benznidazole or matching placebo orally in 2854 patients for 40 to 80 days at 49 centers in Argentina, Bolivia, Brazil, Colombia, and El Salvador. The Population Health Research Institute at Hamilton Health Sciences and McMaster University in Hamilton, Ontario, Canada, and Dante Pazzanese Research Institute in São Paulo coordinated the trial. Ethics approvals were obtained at the coordinating and clinical centers. All the patients provided written informed consent. Full details are provided in the protocol, which is available with the full text of this article at NEJM.org.
Study Population
Inclusion and exclusion criteria have been reported previously. 23 Eligible patients were between 18 and 75 years of age, had at least two positive serologic tests for T. cruzi, and had evidence of cardiomyopathy. (Details are provided in the Supplementary Appendix, available at NEJM.org.) Patients who fulfilled the enrollment criteria were randomly assigned to receive benznidazole or matching placebo. Because of logistic constraints related to the production of benznidazole, the standard regimen (5 mg per kilogram of body weight per day for 60 days) was modified in February 2009 to the administration of a fixed dose of 300 mg per day and a variable duration of therapy (between 40 and 80 days) on the basis of the patient's weight, thereby preserving the total dose. The drug and placebo were purchased at full cost (initially from Roche and later from LAFEPE) by the Population Healthsensitivity analysis on all outcomes including safety, and there were no differences among the batches.)
Study Procedures
Patients were evaluated at 11 days and 21 days, at the end of treatment, at 6 months, and then annually until the end of the study. Adverse events, results of liver-function testing, and findings on 12-lead electrocardiography were recorded at baseline and during each follow-up visit during the treatment period. A 10-ml blood sample to be used for a qualitative conventional PCR assay for the detection of circulating T. cruzi kinetoplast DNA (kDNA) by means of an internationally validated method 24 was obtained from 1896 patients at baseline (after funding was obtained for this purpose), from 1618 patients at the end of treatment, from 1530 patients at 2 years, and from 1487 patients at the final follow-up visit. All negative kDNA results on PCR assay were amplified with human gene-specific primers, which minimized the possibility of false negative results. 25 Methods were standardized across the three core laboratories. (For details, see the Methods section in the Supplementary Appendix.)
Study Outcomes
The primary study outcome in the time-to-event analysis was the first occurrence of death, resuscitated cardiac arrest, insertion of a pacemaker or an implantable cardioverter-defibrillator, sustained ventricular tachycardia, cardiac transplantation, new heart failure, stroke or transient ischemic attack, or a systemic or pulmonary thromboembolic event. An event adjudication committee reviewed all cardiovascular outcomes in a blinded fashion.
Secondary outcomes included the response to treatment on the basis of results on PCR assay overall and according to geographic region corresponding to the common prevalent T. cruzi discrete typing units (i.e., genetic subtypes): T. cruzi I in Colombia and El Salvador, T. cruzi II in Brazil, and T. cruzi V and VI in both Argentina and Bolivia.
26-28
Statistical Analysis
We determined that the enrollment of 2800 patients would provide a power of 90% to detect a relative risk reduction of 26% in the composite outcome in the benznidazole group after a mean of 5 years of follow-up, at a two-sided alpha level of 0.05. This calculation was based on an expected event rate of 8% per year in the control group, an expected rate of nonadherence in the benznidazole group of 17%, and a 3% rate of loss to follow-up. All the patients who underwent randomization were included in the analyses.
In the primary time-to-event analysis, we compared the rate of the first occurrence of any component of the primary composite outcome between the two groups. Data for 14 patients who were lost to follow-up were censored at the last observation.
We assessed the proportionality assumption of the Cox regression model by including a timetreatment interaction term in the Cox model. We used the Cox proportional-hazards model to investigate the influence of important confounders and prognostic factors.
We used generalized estimating equations to determine the proportion of patients with conversion to negative results for T. cruzi on PCR in the two study groups to account for correlation in repeated measures in the same patient with an unstructured correlation matrix. 29 The fixed effects that were included in the model were group, time, and the between-group interaction, and time was assessed with the patient specified as a random variable. Robust variance estimators were used. Treatment effects are summarized by odds ratios with 95% confidence intervals, provided by the logit as the link function.
Categorical variables are presented as numbers and percentages, with P values for the betweengroup comparisons calculated by means of chisquare tests or Fisher's exact tests in cases in which expected numbers were less than five per group. For continuous variables, data were summarized as means and standard deviations, and groups were compared with the use of t-tests. Nonnormally distributed variables are presented as medians and interquartile ranges, with a comparison of groups by means of Wilcoxon ranksum tests. Two-sided P values of less than 0.05 were considered to indicate statistical significance.
We explored the consistency of treatment effects in the 12 prespecified subgroups using tests of interaction in Cox regression models for the primary outcome. We used the same generalized estimating equations to determine the proportion of patients with conversion to negative results for T. cruzi on PCR as we used for the overall results by including two-way and three-way interaction terms. All analyses were performed with the use of SAS software for the UNIX operating system, version 9.2 (SAS Institute), and graphics were produced with the use of TIBCO Spotfire S-Plus for Windows, version 8.2.
R esult s
Study Patients
From November 2004 through October 2011, a total of 2854 patients underwent randomization, with 1431 assigned to the benznidazole group and 1423 to the placebo group (Fig. S1 in the Supplementary Appendix). The majority of the patients were recruited in Brazil (1358 patients), followed by Argentina (559), Colombia (502), Bolivia (357), and El Salvador (78). Most patients (97%) had New York Heart Association (NYHA) class I or II heart failure, and the mean ejection fraction was 55%. The mean (±SD) age was 55±11 years. Baseline characteristics were well balanced between the two study groups (Table 1) . Follow-up data were available for 100% of the patients at 1 year, for 99% at 2 years, and for 99.5% at 7 years. A total of 14 patients (0.5%) were lost to follow-up at the end of the study.
Primary Outcome
The primary outcome occurred in 394 patients (27.5%) in the benznidazole group and 414 patients (29.1%) in the placebo group (unadjusted hazard ratio, 0.93; 95% confidence interval [CI] 0.81 to 1.07; P = 0.31; adjusted hazard ratio, 0.92; 95% CI, 0.81 to 1.06; P = 0.26) ( Table 2 and Fig. 1 ). No significant between-group differences were observed in any component of the primary outcome. In a per-protocol analysis of data from patients who took at least 75% of the target dose, the hazard ratio was 0.90 (95% CI, 0.78 to 1.04; P = 0.16).
Secondary Outcomes
Of the 1896 patients who provided a blood sample for PCR assay before randomization, results were positive in 59.5% of patients in the benznidazole group and in 61.7% of those in the placebo group. Among those with positive results at baseline, PCR conversion rates were 66.2% in the benznidazole group and 33.5% in the placebo group at the end of treatment, 55.4% and 35.3%, respectively, at 2 years, and 46.7% and 33.1%, respectively, at 5 years or more (P<0.001 for all comparisons). Repeated-measures analysis of results on PCR assay showed significantly higher conversion rates in the benznidazole group at all time points, but the relative efficacy appeared to decline over time (odds ratio at the end of treatment, 2.75 [95% CI, 2.24 to 3.36]; odds ratio at 2 years, 2.26 [95% CI, 1.85 to 2.77]; and odds ratio at 5 years or more, 1.78 [95% CI, 1.45 to 2.18]) (P<0.001 for all comparisons). The rate of persistently negative results on PCR among those who had negative PCR results at baseline was also significantly higher in the benznidazole group than in the placebo group (70.3% vs. 59.4% at the end of treatment, P = 0.005; 64% vs. 54.1% at 2 years, P = 0.03; and 63% vs. 52.4% at 5 years or more, P = 0.02). New abnormalities on electrocardiography occurred in 36.7% of the patients in the benznidazole group and in 35.6% of those in the placebo group at 2 years (odds ratio, 1.05; 95% CI, 0.89 to 1.24) and in 38.2% and 38.2%, respectively, at 5 years or more (odds ratio, 1.00; 95% CI, 0.84 to 1.19).
Subgroup Analysis
The patients' PCR status at baseline did not have a significant effect on the primary clinical outcome; among patients with PCR-positive status, 24.6% of the patients in the benznidazole group and 26.9% of those in the placebo group had a primary clinical event (hazard ratio, 0.91; 95% CI, 0.73 to 1.14), and among those with PCRnegative status, 23.7% of the patients in the benznidazole group and 25.3% of those in the placebo group had a primary clinical event (hazard ratio, 0.92; 95% CI, 0.69 to 1.23) (P = 0.96 for interaction) (Fig. 2) .
T. cruzi genotypes can differ among geographic locations, which can affect patients' responses to benznidazole. 26 * Plus-minus values are means ±SD. There were no significant differences between the groups except for Q waves (P = 0.009). ACE denotes angiotensin-converting enzyme, and ARB angiotensin-receptor blocker. T (Fig. 2) . There was no significant difference in treatment response on the basis of individual markers of clinical severity, including NYHA class, cardiothoracic ratio of more than 0.5, segmental or global wall-motion abnormalities, low QRS voltage, left ventricular end diastolic diameter of more than 5.0 mm, or left ventricular ejection fraction of less than 40%, or on the basis of sex or age (Fig. 2) .
The treatment response on the basis of PCR conversion for the 12 subgroups that were analyzed indicated a significant difference in response according to country (P<0.001 for interaction) (Fig. 3) . No other significant interactions were observed on the basis of PCR conversion.
Study-Drug Adherence and Safety
Adherence to the study-drug protocol (receipt of ≥75% of the target dose) was reported in 84% of the patients in the benznidazole group and in 94% of those in the placebo group. The rate of drug interruption because of an adverse event was significantly higher in the benznidazole group than in the placebo group (23.9% vs. 9.5%, P<0.001). Cutaneous rash, gastrointestinal symptoms, and nervous system disorders were the most common reasons for drug interruptions (Table 3) . 
Discussion
Benznidazole did not significantly reduce the rate of the primary clinical outcome, despite reductions in the parasite detection in serum samples. Rates of conversion to negative PCR results varied significantly according to geographic location, but the difference in rates of conversion did not correspond to a difference in the rates of clinical outcomes. The effects of benznidazole on both clinical outcomes and rates of conversion to negative PCR results did not vary according to disease severity. The role of treatment in patients with chronic Chagas' disease and the effect of such treatment on the progression of the disease are unclear, since data have been reported only from observational and small, randomized studies. [19] [20] [21] [22] 30, 31 A meta-analysis that combined data from both observational cohorts and small, randomized trials showed that benznidazole had significant activity against T. cruzi, as assessed by either seroconversion or significant reductions in antibody titers. 32 This meta-analysis included nine studies (of which only three, involving a total of 285 patients, were randomized trials, two of which involved children) focusing on chronic Chagas' infection with no evidence of cardiomyopathy. The use of benznidazole, as compared with placebo or no treatment, increased the rate of favorable response, which was defined as negative serologic results or xenodiagnosis (global odds ratio, 18.8; 95% CI, 5.2 to 68.3). In an observational study, Viotti et al. 20 found a significantly lower risk of clinical events (including a change in the Kuschnir classification Shown is the rate of the primary composite outcome (death, resuscitated cardiac arrest, sustained ventricular tachycardia, insertion of a pacemaker or implantable cardioverter-defibrillator, cardiac transplantation, new heart failure, stroke or transient ischemic attack, or other thromboembolic event) among patients in the benznidazole group and the placebo group during a 7-year period (hazard ratio in the benznidazole group, 0.93; 95% CI, 0.81 to 1.07; P = 0.31 by the log-rank test). The inset shows the same data on an enlarged y axis. T h e ne w e ngl a nd jou r na l o f m e dicine Shown are hazard ratios for the primary outcome in all 12 prespecified subgroups in the benznidazole group and the placebo group, according to clinical characteristics and results on electrocardiography and two-dimensional echocardiography indicating the severity of disease. Rates of the primary outcome in the two groups are presented with a mean of 5.4 years of follow-up. The size of the squares is proportional to the size of the subgroup. The subgroup according to age was defined on the basis of the median age of 56 years. The disease-severity score was calculated as follows: New York Heart Association class III (5 points), cardiothoracic ratio of more than 0.5 (5 points), regional wall-motion abnormalities (3 points), complex ventricular arrhythmias (3 points), low-voltage QRS complex (2 points), and male sex (2 points). A low score ranges from 0 to 2, an intermediate score ranges from 3 to 5, and a high score is more than 5. For the primary outcome, the presence or absence of baseline therapy with amiodarone was the only subgroup that showed significant heterogeneity. PCR denotes polymerase chain reaction, and RBBB right bundle-branch block. previous studies were small and most were nonrandomized, and the studies enrolled primarily patients without cardiomyopathy. Second, the rates of loss to follow-up were higher than those in our study (20% vs. 0.5%). Third, the studies did not evaluate outcomes such as total rates of death, heart failure, or any of the composite outcomes that we analyzed. Shown are odds ratios for conversion to negative results for Trypanosoma cruzi on PCR assay at the end of the treatment period, according to 11 of the 12 prespecified subgroups. The size of the squares is proportional to the size of the subgroup. Odds ratios and 95% confidence intervals were calculated from repeated-measures analysis with the use of generalized estimating equations (GEE), with a comparison of values at all three follow-up periods (after treatment, at 2 years, and at 5 years or more) with those at baseline. (Odds ratios for patients' PCR status at baseline are not shown, as indicated by asterisks, because these data were not analyzed in a GEE model.) Copyright © 2015 Massachusetts Medical Society. All rights reserved.
T h e ne w e ngl a nd jou r na l o f m e dicine
Benznidazole typically clears parasite detection in approximately 94% of patients who are in the indeterminate phase of the disease (i.e., have positive serologic findings but no evidence of cardiac damage), with effects sustained for at least 1 year. 34 In contrast, in our study involving only patients with established Chagas' cardiomyopathy, the efficacy of treatment as assessed by conversion to negative PCR results was more modest, with rates of 66% at the end of treatment and 46.7% after 5 years or more, which suggests that the standard regimen of benznidazole may be less effective in patients with established cardiomyopathy. Genetic subtypes of T. cruzi vary according to the geographic location. Since we did not have genotype information, we had to infer that patients in certain geographic regions were likely to have distinct T. cruzi strains. On the basis of this assumption, we observed significant differences among countries in the PCR response to therapy (Fig. 3) . This finding may explain the lack of overall reduction in the primary outcome, but we did not observe consistently parallel results on clinical outcomes. We did not find any significant effect of therapy on the primary outcome even after adjustment for disease severity or the risk status of the patients. Only the subgroup receiving amiodarone (a high-risk group) appeared to benefit from therapy, but this result should be viewed with caution, since a large number of subgroup analyses were performed and rates of parasite detection on PCR in the benznidazole group were similar regardless of the receipt of amiodarone at baseline. However, this intriguing observation may require further exploration. 35 Although our study was a large trial involving patients with established Chagas' cardiomyopathy, we could have missed small differences in risk (e.g., a relative risk reduction of 10%). The 95% confidence intervals in our analyses rule out a relative risk reduction of 20%, which is smaller than the difference that the study was designed to detect. Variable responses to benznidazole have been reported previously and may have contributed to our neutral findings. 36 Future analyses of stored blood samples by means of quantitative PCR and genotyping may provide a more precise characterization of T. cruzi that can be used to assess whether genotype influences the clinical response to benznidazole.
It is possible that the benefit of benznidazole may be observed in patients who are at very low risk before the appearance of cardiac damage or that the benefit may accrue with more prolonged therapy (as is the case with therapy for some other chronic infections, such as tuberculosis or leprosy), with repeated pulses of benznidazole, or with treatment at an earlier stage of the disease. These hypotheses are untested. Whether longer follow-up is needed to detect the emergence of a benefit is also a consideration but is speculative, since 60% of our patients were followed for more than 6 years and 25% for more than 7 years, and no obvious signal of possible benefit was observed. Our findings do not challenge current guidelines that recommend treatment with trypanocidal therapy in the early stages of chronic Chagas' infection (which are based on several studies, 37, 38 including one that showed the benefit in preventing congenital transmission 39 ) and should not detract from the pursuit of general goals for exploring more effective or earlier treatments with new drugs or drug combinations. 40 It is notable that 13.4% of patients permanently discontinued treatment with benznidazole because of adverse events, a rate that is lower than that previously reported in observational and small, randomized trials and supports the concept that repeated trypanocidal treatment may be feasible.
In conclusion, among patients with established Chagas' cardiomyopathy, benznidazole treatment significantly reduced the detection of circulating parasites but did not reduce cardiac clinical progression.
